Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 8, 2018. The report disseminates a press release from ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The announcement details the launch of the TANGO study, the eighth phase III trial in ViiV's two-drug regimen (2DR) program for HIV-1 treatment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding clinical trial activities and does not contain financial statements or quantitative financial performance data.
Material Changes and Operational Updates
The primary material update is the initiation of the TANGO study. This phase III, randomized, open-label, active-controlled study aims to enroll approximately 550 adults with HIV-1 across North America, Europe, Australia, and Japan. The study investigates whether patients currently virally suppressed on a three-drug tenofovir alafenamide fumarate (TAF)-based regimen can maintain suppression by switching to a two-drug regimen of dolutegravir (TIVICAY) and lamivudine (EPIVIR). This follows the GEMINI studies, which investigated the same 2DR in treatment-naive patients, with results anticipated later in 2018.
Guidance, Outlook, and Risks
Outlook and Management Commentary: ViiV Healthcare aims to evolve HIV treatment by reducing the number of drugs patients must take while maintaining efficacy. John C. Pottage, Jr., MD, Chief Scientific and Medical Officer, stated that if the TANGO data supports the switch, it could address long-term toxicity issues by reducing lifetime exposure to antiviral agents. Results from the TANGO study are expected in 2019.
Risks and Contingencies: The filing includes standard safety warnings for the drugs involved:
- TIVICAY (dolutegravir): Risks include hypersensitivity reactions (potentially life-threatening), hepatotoxicity (including acute liver failure), and drug interactions. It is contraindicated in patients with previous hypersensitivity to dolutegravir or those receiving dofetilide.
- EPIVIR (lamivudine): Risks include lactic acidosis, severe hepatomegaly, and severe acute exacerbations of hepatitis B upon discontinuation. It is contraindicated in patients with previous hypersensitivity to lamivudine.
Forward-Looking Statements: GSK cautions that projections regarding study results and timelines are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the enrollment progress and timeline for the TANGO study (target: ~550 patients, results expected 2019).
- Monitor the anticipated 2018 results from the GEMINI 1 and 2 studies (treatment-naive patients) and the ATLAS/FLAIR studies (long-acting injectables).
- Review the safety profile of dolutegravir and lamivudine, specifically regarding hepatotoxicity and hypersensitivity, as these impact long-term patient adherence and liability.
- Confirm the ownership structure and financial reporting of ViiV Healthcare as a majority-owned subsidiary of GSK.